Mayne Pharma Group Limited (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Limited (ASX: MYX)
Latest News
Share Gainers
Why Arafura, Core Lithium, Mayne Pharma, and Newcrest shares are storming higher
Share Market News
Multiple directors are buying this beaten-up ASX 300 healthcare stock
Share Market News
4 ASX 300 directors buying up their company shares in the past week
Share Gainers
Why Allkem, Argosy Minerals, Mayne Pharma, and NextDC shares are racing higher
Earnings Results
Guess which ASX 300 share has rocketed 27% in 2 days since reporting
Share Gainers
Why De Grey, Kogan, Mayne Pharma, and Mesoblast shares are charging higher
Share Fallers
Why Gold Road, MA Financial, Mayne Pharma, and Westgold shares are dropping today
Share Market News
Why Arafura, Mayne Pharma, Pilbara Minerals, and Tyro shares are dropping today
Share Fallers
Why Coronado, IDP, Mayne Pharma, and Rio Tinto shares are dropping today
Share Fallers
Why Bubs, Collins Foods, Dusk, and Mayne Pharma shares are falling today
Share Fallers
Why is this ASX All Ords share crashing 27% today?
Share Gainers
Why Cogstate, Mayne Pharma, Race Oncology, and Whitehaven Coal are charging higher
Frequently Asked Questions
-
Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.
-
Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mayne Pharma Group Limited
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.
Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market.
